NEW YORK CITY, NY / ACCESS Newswire / May 14, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Entrada Therapeutics, Inc. ("Entrada" or "the Company") (NASDAQ:TRDA). Investors who purchased Entrada securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TRDA.

Entrada Investigation Details

On May 7, 2026, Entrada issued a press release announcing "topline data from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose (MAD) portion of the Phase 1/2 ELEVATE-44-201 clinical study." Although Entrada characterized the results as "positive", the study only showed a 2.36% increase in production of dystrophin, a protein that is critical for muscle protection and does not appear at adequate levels in Duchenne patients-significantly less than necessary to make the drug competitive against other treatments. Following this news, Entrada's stock price fell $9.18 per share, or 57.27%, to close at $6.85 per share on May 7, 2026.

What's Next for Entrada Investors?

If you are aware of any facts relating to this investigation or purchased Entrada securities, you can assist this investigation by visiting the firm's site: bgandg.com/TRDA. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911

No Cost to Entrada Investors

We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Entrada Securities Investigation?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | info@bgandg.com

Attorney advertising.

Prior results do not guarantee similar outcomes.

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View the original press release on ACCESS Newswire

COMTEX_479130975/2457/2026-05-14T11:00:13